Lung Cancer -

icnet.uk - by Moose and Doc

lung cancer icnet.uk Moose and Doc Lung Cancer

April 29, 2015 By Steven Halls

This page is the continuation of references in support of Section 6G

REFERENCES

Alizadeh, A.A., Ross, D.T., Perou, C.M., van de Rijn, M. (2001). Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol 195, 41–52. (Retrieved 19th Feb 2015): http://onlinelibrary.wiley.com/doi/10.1002/path.889/abstract;jsessionid=9863A22FF62CA10EE7AE6EC1F456D211.f04t04

Alphy RJ, Sreelekha TT. (2012) Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer International: Article ID 729532 (Retrieved 19th Feb 2015): http://www.hindawi.com/journals/lci/2012/729532/

Awad MM, Shaw AT.(2014) ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond. Clin Adv Hematol Oncol. Jul; 12(7): 429–439. (Retrieved 29th April 2015): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215402/

Clark GM. (2007) Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Molecular Oncology: Volume 1, Issue 4: Pages 406–412. (Retrieved 29th April 2015): http://www.sciencedirect.com/science/article/pii/S1574789107001020

Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV. et al. (2002) p63 Expression Profiles in Human Normal and Tumor Tissues. Clin Cancer Res February 8;494 (Retrieved 28th April 2015): https://www.ncbi.nlm.nih.gov/pubmed/11839669

Gazdar AF, Schiller JH. (2011) Predictive and Prognostic Factors for Non–Small Cell Lung Cancer—Potholes in the Road to the Promised Land. JNCI J Natl Cancer Inst (2011) 103 (24): 1810-1811. (Retrieved 29th April 2015): http://jnci.oxfordjournals.org/content/103/24/1810.full

Goldstein, N.S., Hewitt, S.M., Taylor, C.R., et al. (2007). Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15, 124–33. (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pubmed/17525622?dopt=Abstract

Lindeman NI, Cagle PT, Beasley MB, et al. (2013). Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137(6),828-860. (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162344/

Weinstein IB. (2002). Addiction to oncogenes: the Achilles heel of cancer. Science 297 63–64. (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pubmed/12098689

 

Did you click on any pictures to hear music, or find other surprises?.

 

Copyright © 2014–2022 · by Steven Halls, MD · steve@halls.md ·1-780-608-9141 · Log in